RNS Number : 0703X
Shield Therapeutics PLC
13 February 2025

Shield Therapeutics plc
("Shield Therapeutics" or the "Company")

PDMR Transaction Notification

London, UK, 13 February 2025: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company specialising in iron deficiency, confirms that Mr Anders Lundstrom, Chief Executive Officer, acquired 575,000 Ordinary Shares in the Company on 13 February 2025 at a price of 3.7p per share. Mr Lundstrom now holds a beneficial interest in 585,000 Ordinary Shares.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Anders Lundstrom</td></tr>
<tr><td>2.</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a.</td><td>Position/status</td><td>Chief Executive Officer</td></tr>
<tr><td>b.</td><td>Initial notification /Amendment</td><td>Initial</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>Shield Therapeutics plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>213800G74QWY15FC3W71</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Ordinary shares of 1.5p each in the capital of the Company

ISIN of Ordinary Shares: GB00BYV81293</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Acquisition of Ordinary Shares</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>3.7p</td><td>575,000</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>575,000

£21,275</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>13 February 2025</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>AIM</td></tr>
</table>

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Anders Lundstrom, CEO +44 (0) 191 511 8500

Santosh Shanbhag, CFO Investorrelations@shieldtx.com
Stephanie Hicks, Investor Relations

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel / Patrick Birkholm +44 (0)20 7418 8900

Joint Broker +44 (0)20 7220 0500
Cavendish Ltd
Geoff Nash / Rory Sale / Nigel Birks / Harriet Ward

Financial PR & IR Advisor
Walbrook PR
Alice Woodings / Lianne Applegarth +44 (0)20 7933 8780 or shield@walbrookpr.com

About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.The drughas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:www.accrufer.comandwww.feraccru.com.

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU® is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR®/ FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.

ACCRUFeR®/FeRACCRU® has patent coverageuntil the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAKADFESSEFA